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Abstract 
Background: Acute lymphoblastic leukemia (ALL) comprises a heterogeneous group of disorders which originate 
from various important genetic lesions in B and T progenitor cells, including mutations that lead to stage-specific 
developmental arrest and those that impart the capacity for unlimited self-renewal, resulting in clonal expansion of 
immature progenitor cells. Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks 
between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous exposures, genetic 
susceptibility, and chance have roles. Survival in pediatric acute lymphoblastic leukaemia has improved to roughly 
90% in trials with risk stratification by biological features of leukaemic cells and response to treatment, treatment 
modification based on patients' pharmacodynamics and pharmacogenomics, and improved supportive. The promoter 
methylation pattern of DNA in cancer cells is different with the normal cells. Suppressor with morphogenetic effect 
on genitalia family member (SMG1) belongs to a family of phosphoinositide 3-kinase-related kinases and is the 
main kinase involved in nonsense-mediated mRNA decay.  
Materials and Methods: This study was performed to investigate the correlation between SMG1 promotor 
methylation and its expression levels in acute lymphoblastic leukemia using methylation specific PCR (MSP). Our 
patients and control samples were collected from Children's Medical Center of children medical center of Imam 
Khomeini  hospital of Tehran. To confirm the MSP results, we used Quantitative Real time-PCR (qRT-PCR ) to 
measure the expression level of mRNA to find out if there is any relation between pattern of methylation and 
expression.  
Results: After performing MSP, we found that SMG1 promoter was hypermethylated. Hyper methylation of SMG1 
was detected in 67/74% (21/31) of ALL samples compared to control group. SMG1 mRNA expression was down- 
regulated 2.74 fold  compared to control group.  
Conclusion: The aim of this study was to investigate the effect of methylation pattern on gene expression. Our 
findings suggest that SMG1 acts as a functional tumor suppressor gene which was down-regulated by CpG islands 
hypermethylation in ALL patients. It was shown that the methylation of SMG1 was occurred in the 67/74% of 
samples. 
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Acute lymphoblastic leukemia (ALL) is the 
most common cancer in children and occurs with 
high frequency in childhood and is associated with 
high mortality in adults. So, the detection of residual 
leukemic cells (minimal residual disease, MRD) is 
the most important prognostic factor to identify high 
risk patients(1). 
Patients are mainly children; roughly 60% of 
cases occur in people aged younger than 20 years 
(1),(2, 3)  and Survival in childhood acute 
lymphoblastic leukemia is approaching 90% (3) but 
treatment in infants (i.e, children younger than 12 
months) and adults needs improvement (4, 5). 
T-cell acute lymphoblastic leukemia (T-ALL) 
is an aggressive blood malignancy that arises from 
the malignant transformation of T-cell progenitors 
and is predominantly diagnosed in children and 
adolescents where it accounts for 10–15% of ALL 
cases with a second peak of recurrence in aged adults 
(25% of adult ALL cases) (6). During this maturation 
process, cooperation between a variety of oncogenes 
and tumor suppressors can drive immature 
thymocytes into uncontrolled clonal expansion and 
cause T-cell acute lymphoblastic leukemia (T-ALL). 
Recent genetic studies have identified recurrent 
somatic alterations in genes involved in DNA 
methylation and post-translational histone 
modifications in T-ALL, suggesting that epigenetic 
homeostasis is critically required in restraining tumor 
development in the T-cell lineage. 
Recent studies have proved that, not only the 
successive accumulation of genetic alterations in 
oncogenes and tumor suppressor genes, but also the 
epigenetic alterations contributed to 
carcinogenesis(7). 
Epigenetic is a mechanism of gene expression 
regulation that does not alter gene sequence (8, 9). 
The most commonly occurring epigenetic event is 
DNA methylation at cytosine that precedes guanine 
in the DNA sequence, the CpG dinucleotides. The 
addition of a methyl group at the carbon 5 position of 
the cytosine ring is catalyzed by DNA 
methyltransferases (DNMTs) (8, 10). Due to the high 
mutagenic potential of 5-methylcytosine, CpG 
dinucleotides are irregularly distributed along human 
genome. There are CpG-rich regions—the CpG 
islands—in the regulatory region of many genes, 
namely tumor suppressor genes. In general, CpG 
islands are normally unmethylated, but repetitive 
genomic sequences and introns are hypermethylated 
(10, 11). 
SMG1 is a common tumor suppressor gene. 
SMG1 is a PI3K-related kinase (PIKK) associated 
with multiple cellular functions, including DNA 
damage responses, telomere maintenance, and 
nonsense-mediated mRNA decay (NMD). NMD 
degrades transcripts that harbor premature termination 
codons (PTCs) as a result of events such as mutation 
or alternative splicing (AS). Recognition of PTCs 
during NMD requires the action of the upstream 
frameshift protein (Upf1) which must be 
phosphorylated at first by SMG1. However, the 
physiological function of mammalian SMG1 is not 
known (12). 
Methods 
Patients and WBC isolation. A total of 31 
subjects including leukemia patients (10 men and 21 
women),with a mean age of 4/6 years (range 1-12) and 
5 healthy controls were participated in this study. 
Before beginning, we collected consent from their 
parents. The clinical data for leukemia patients are 
shown in Table1. 
Peripheral blood (5ml) samples were collected 
and transferred to laboratory. After that, the RNA and 
DNA extraction process was done. Mononuclear cells 
of drawn samples including leukemic blast cells were 
isolated by concentration gradient sedimentation using 






11.7 WBC count (109/lit) 
1.37 Hb (g/dl) 
61.90 Platelet count (109/lit) 
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Ficoll-hypaque (GE Healthcare, Waukesha, WI, 
USA) .We extract the DNA with GENE ALL kit 
(qiagene) according to the manufacturer’s procedure, 
then they treated with bisulfite by using the FAST 
Epi Tec Bisulfite Kit (Qiagene59824) according to 
the manufacturer’s instructions.  
Total RNA extraction and cDNA synthesis. 
Total RNA were extracted from fresh peripheral 
blood of ALL patients using TRIzol reagent 
(Invitrogen, Cat num. 15596-026). 6 µL of purifies 
RNA were used for the quality control purposes and 
the rest were stored at -70°C or used immediately for 
cDNA synthesis. To check the quantity and quality 
of RNA, we used both nano-drop device 
(Thermoscientific) and electrophoresis on 1% 
formaldehyde agarose gels.  
MSP. We used MSP for investigating the 
methylation pattern of SMG1 promoter. For this 
reason, we used 2 pairs of primers specified for 
checking the methylated and unmethylated residue . 
Primer design for qRT-PCR. All the mRNA 
transcript sequences of the SMG1 and GAPDH (as 
reference gene) genes were downloaded from NCBI 
(www.ncbi.nlm.nih.gov) and Ensemble 
(www.Ensemble.org) databases. We performed a 
multiple sequence alignment using MEGA6 software 
to select a conserved region in order to amplify all 
the possible variants of the target genes. Then, the 
conserved regions were inserted into Oligo7 software 
for qRT-PCR primer design  
After designing, the primers were analyzed by 
NCBI BLAST. The BLAST results also showed high 
specific primers for all target genes which amplify 
almost all of the important mRNA variants. The 
primer pairs information for the target gene and 
reference gene are mentioned in the following table 
(Table3). 
Real Time PCR. In order to investigate whether 
the promoter hypermethylation of SMG1 gene results 
in the reduced SMG1 expression or not, we performed 
qRT-PCR to detect the SMG1 expression in ALL 
patients and control group. We used ABI7500 for our 
experiment. Melting curve  analysis was performed for 
both genes at the end of each run. Because of their 
efficiency, difference was less than 3%, so analysis of 
the expression result was done with 2−ΔΔCt method 
that shows the expression changes. Specificity of 
experiment was investigated by melt curve and 
electrophoresis. Real time PCR was carried out in 
volume of 20µl containing: 10µl qPCR master mix 
(Amplicone), 2µL of cDNA and 1µl mixed forward 
and reverse primers and 7 µl ddH2O. GAPDH was 
used as housekeeping gene. 
Statistical analysis. For all calculations, SPSS 
(Statistical Package for Social Sciences) software 
version 20 was employed. The Mann-Whitney U test 
was used to compare SMG1 expression level in 
methylated and unmethylated group. A p-value of less 
than 0.05 was regarded as statistically significant. 
Results 
All samples were used in real time PCR. The 
 
Table 2: Primer sequence (M and U stand for methylated and unmethylated, respectively) 
SMG1 M-forward primer sequence 5'-GCGTACGTGAATTTAAGGGTAC-3' 
SMG1 M-reverse primer sequence 5'-AACAAAAAATCTCCACTACTACGAC-3' 
SMG1 U-forward primer sequence 5'-GGTGTATGTGAATTTAAGGGTATGT-3' 
SMG1 U-reverse primer sequence 5'-AACAAAAAATCTCCACTACTACAAC-3' 
  




282 GTG GAG AGT TAC GCA GTC TT F SMG1 
282 CGC ATA ATG TGT AAA ACCTGCTC R SMG1 
114 GCTCTCTGCTCCTCCTGTTC F GAPDH 
114 CGACCAAATCCGTTGACTCC R GAPDH 
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ratio of SMG1 to GAPDH transcripts was reduced 
2.74 folds in the methylated group compared to that 
in the control group. These results strongly indicated 
that hypermethylation in the promoter region of 
SMG1 gene was responsible for the lower expression 
of SMG1 in ALL. 
SMG1 promoter is completely methylated in 
21 patients (67.7%) and completely unmethylated in 
9 patients (29.1 ℅). None of control individuals 
showed methylation in SMG1 gene. 
In ALL patients, hypermethylation frequency 
of SMG1 was 67.7% (22 out of 31 patients). 
Discussion 
While cancer has been long recognized as a 
disease of the genome, the importance of epigenetic 
mechanisms in neoplasia was acknowledged more 
recently. The most active epigenetic marks are DNA 
methylation and histone protein modifications and 
they are involved in basic biological phenomena in 
every cell. Their role in tumorigenesis is stressed by 
recent unbiased large-scale studies providing 
evidence that several epigenetic modifiers are 
recurrently mutated or frequently dysregulated in 
multiple cancers. The interest in epigenetic marks is 
especially due to the fact that they are potentially 
reversible and thus druggable (13).  
Epigenetic and its different mechanism are an 
important part of the gene expression regulation. 
Epigenetic changes lead cause to distinctive changes 
in gene expression that occur without any change in 
the gene sequence. Epigenetic is study of chromatin 
biochemical changes consists of DNA methylation 
and various histone modifications and changes in 
non-coding micro-RNA that each of these 
mechanisms can affect gene expression and gene 
silencing without sequence changing. 
Tumor suppressor genes silencing, is a 
common phenomenon in cancer. In fact, methylation 
is one of the most common mechanisms of gene 
silencing in most of suppressor genes. DNA 
methylation is an enzyme depends on 
chemical modification that alters structure of DNA 
bases. 
In vertebrates, methylation occurs in cytosine 
in the 5' with a guanine. Methyl cytosine bases are 
approximately constituted of 1% of the human 
genome that 70 to 80 percent of which located in CpG 
islands. Most of the CpG islands (94%) 
are remain unmethylated in normal cells and gene 
expression occurs based on the need of cell (14). 
In present study, we investigated the 
methylation pattern of SMG1 promoter in 31 ALL 
patients at diagnosis stage and before treatment and in 
the 5 blood samples of normal people. Our study is the 
second research about the SMG1 methylation in 
hematological malignancies. Before this, there is only 
one study which investigate the methylation of SMG1 
promoter in ALL (15) and is the first study in which 
we found that the SMG1 mRNA expression was 
downregulated because its promoter was 
hypermethyaled in ALL. 
The first study about SMG1 in leukemia is 
about AML which was done in 2014 and studied the 
methylation pattern and its expression. Their results 
showed that SMG1 was hypermethylated in AML and 
it was down-regulated. Our results showed that 21 out 
of 31 ALL patients that are in the first stage of ALL 
diagnosis, have methylated SMG1, in other words, in 
67.7% of ALL samples before diagnosing, 
hypermethylation was occurred whereas no 
methylation was seen in the normal group. In addition, 
we measured the expression levels of SMG1 mRNA in 
patients with real time PCR. The results indicate that 
expression level in samples with methylation is 2.74-
fold lowered compared to normal control samples. 
The most direct mechanism by which DNA 
methylation can interfere with transcription is to 
prevent the binding of basal transcriptional machinery 
or ubiquitous transcription factors that require contact 
with cytosine in the major groove of the double helix. 
From another point of view CpG island chromatin is 
enriched in hyperacetylated histones and deficient in 
linker histones. These are essential features of 
transcriptionally competent chromatin templates. In 
contrast, chromatin assembled on artificially 
methylated DNA becomes associated with 
hypoacetylated histones, refractory to nuclease or 
restriction endonuclease digestion and 
transcriptionally silent (16). 
In another study which was done in 2016 by 
Patricia Rebeiro, Alexander James, they investigated 
the role of SMG1 expression in B cell 
lymphoproliferative disease. 
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Loss of SMG1 leads to the development of B 
cell lymphoproliferative disease in mice. However, 
this has not been studied in humans. The aim of their 
project is to correlate SMG1 expression in human B 
cell lymphoproliferative disease with clinical 
characteristics, histology, karyotype, response to 
therapy and prognosis. This is done by 
immunoblotting on purified clonal B cells in human 
blood and tissue microarray on human lymphoma. 
Preliminary results show that there is significant 
heterogeneity in SMG1 expression in chronic 
lymphocytic leukemia and mantle cell lymphoma. 
This study highlights a potential important pathway 
in the pathogenesis and treatment of B cell 
lymphoproliferative disease (17). 
In other studies, the tumor suppressor role 
of SMG1 and the alternation of its expression 
level were studied in other cancers. For example, in a 
study conducted in 2010, SMG1 role as a NMD 
physiological factor was studied. NMD in addition to 
its role in removing of the mRNA with premature 
stop codon, SMG1 has an important role in the 
regulation of many RNA-binding transcription 
factors, too. In this study with SMG1 nude mouse 
model, they demonstrated that it is necessary for 
embryonic development and in its absence, mRNAs 
with PTCs will remain in the cell (18). 
In a study of hepatocellular carcinoma that 
was conducted in 2015, it has been concluded that 
the AZD5363 inhibits AKT pathway downstream 
molecules and mTOR and SMG1 activation  
dependon the cell type involved in  the cancer (19). 
In another study in 2013, it was reported that 
SMG1 regulates the G1/S check point cell cycle due 
to radiation response by phosphorylation of p53. It 
causes its stability and activation. In fact, cell cycle 
and tumor growth regulation are done in p53 
dependent pathway. SMG1 inhibits CDK2 in 
response to DNA damage.  
In another study that was done in 2011 by HH 
cheung et al, the regulatory role of SMG1 and NIK in 
apoptosis induced by SMCs (Smac mimetic 
compounds) has been investigated. SMCs are 
experimental small molecules that induce tumor 
necrosis factor alpha. They indicated that such 
protein kinases like NIK and SMG1 have an 
important role in protecting cancer cells in induced 
Smac-mediated TNF-α apoptosis. In fact, they found a 
new role for SMG1 and NIK as SMCs -mediated 
TNF-α induced inhibitors (20).  
Conclusion 
Taken together, our findings show that SMG1 
as a tumor suppressor gene was down-regulated by 
CpG island hypermethylation in ALL patient. The 
methylation of SMG1 was occurred in the 67/74% of 
samples. The SMG1 mRNA expression level of 
methylated samples is 2.74 fold lower than the  normal 
group. It is recommended to conduct more studies to 
determine the role of hypermethylation of SMG1 in 
the pathogenesis of ALL or in ALL subtypes and other 
hematologic malignancies and observe an association 
between methylation of SMG1 and clinical findings in 
ALL patients such as age, sex, WBC, platelet count 
and complete remission after induction therapy 
.Moreover investigations of other regulation 
mechanism of SMG1 in ALL are needed. We also 
suggest to use other methylation technics to 
investigate the methylation pattern and also study the 
ALL in cell lines. 
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